Editas Medicine
Pioneering the Possible
Dedicated to developing a robust pipeline of medicines to treat people living with serious diseases around the world.
About
Editas Medicine is a leading genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases. Our corporate headquarters is located in Cambridge, MA, and we have a significant and growing site in Boulder, CO. We are pioneering the possibilities of genomic medicines through gene editing. Jump down to learn more about our work and the people who make it possible.
The Editas Medicine Mission
Our mission is to translate the power and potential of genome editing into a broad class of gene edited medicines that transform lives of people living with serious diseases.
We’re using CRISPR, a powerful genome editing technology to develop new gene edited medicines. We are researching and developing both in vivo gene edited medicines, which edit genes inside the body, and ex vivo gene edited cell medicines, where editing occurs in cells outside the body and those edited cells are transferred into patients.
